Opko Health (OPK) Q3 FY2026 earnings: revenue $65 million, up 15.9% on the year

Opko Health, Inc. (OPK) reported revenue of $65 million for Q3 FY2026, the quarter ended 30 September 2026, up 15.9% on the same quarter a year earlier as the company restated it. Net income was -$54 million, and diluted earnings per share $-0.07. The figures are the company's own, from the 10-Q it filed with the SEC on 4 November 2026.

Revenue

$65 million

-56.9% on the year · -60.0% on the quarter

Q4 FY2024Q3 FY2026

Operating margin

-48.0%

31.7% a year earlier

Q4 FY2024Q3 FY2026

Net income

-$54 million

Q4 FY2024Q3 FY2026

Diluted EPS

-$0.07

Q4 FY2024Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 raised, 3 narrowed, 9 new, 1 kept.

Revenue rose 16 percent: Continuing-operations revenue rose to $65.4 million from $56.4 million, mainly on higher Lilly royalty revenue, higher Rayaldee sales and growth in international operations.
Global Products moved to operating income: Global Products revenue rose to $48.4 million from $39.4 million; segment operating income was $6.0 million against an operating loss of $1.2 million.
BioReference loss against prior gain: Loss from discontinued operations was $18.0 million, against income of $54.6 million; the 2025 result included a $101.6 million gain on the sale of BioReference’s oncology diagnostics business.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	65.4	164	152	-60.0%	-56.9%
Cost of revenue	23.4	83.6	21.4	-72.1%	+9.2%
Gross profit	42.1	80.0	49.9	-47.4%	-15.7%
Gross margin	64.3%	48.9%	32.9%
Research and development	32.2	33.2	29.8	-3.0%	+8.0%
Selling, general and administrative	24.8	52.9	53.8	-53.1%	-53.8%
Operating income	-31.4	-7.0	48.1
Operating margin	-48.0%	-4.3%	31.7%
Interest expense	13.5	11.4	11.3	+18.2%	+18.8%
Pre-tax income	-42.9	-13.4	-41.0
Income tax	-7.3	-5.0	19.8
Net income	-53.5	-8.4	21.6
Net margin	-81.8%	-5.1%	14.3%
Diluted EPS	-$0.07	-$0.01	$0.03

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-36.3	-43.5	-34.6
Capital expenditure	2.8	3.0	3.1	-7.3%	-11.1%
Free cash flow	-39.1	-46.5	-37.8
Free cash flow margin	-59.8%	-28.4%	-24.9%
Cash from investing	11.3	15.5	195	-27.3%	-94.2%
Cash from financing	114	-13.0	-16.2
Depreciation and amortisation	18.9	22.4	22.7	-15.5%	-16.7%
Share-based compensation	1.8	2.2	3.0	-18.2%	-40.0%
Buybacks	10.6	13.0	15.3	-18.3%	-30.4%
Diluted shares, weighted	746m	755m	780m	-1.2%	-4.3%
Shares outstanding at period end	743m	746m	768m	-0.5%	-3.3%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	1,116	1,184	1,305	-5.7%	-14.5%
Debt	477	349	344	+36.8%	+38.7%
Operating lease liabilities	26.8	34.0	36.3	-21.0%	-26.0%
Finance lease liabilities	2.6	2.7	3.4	-0.4%	-21.4%
Other liabilities	257	260	306	-0.9%	-16.0%
Total liabilities and equity	1,880	1,829	1,996	+2.8%	-5.8%
Fixed assets	68.0	71.5	75.0	-4.8%	-9.3%
Goodwill	317	482	484	-34.1%	-34.4%
Intangible assets	396	478	535	-17.0%	-26.0%
Investments	44.5	40.2	13.4	+10.6%	+232.9%
Cash and equivalents	384	301	412	+27.7%	-6.8%
Receivables	80.2	81.9	94.6	-2.0%	-15.2%
Inventory	50.6	61.9	65.0	-18.2%	-22.1%
Other assets	539	314	316	+71.7%	+70.6%
Total assets	1,880	1,829	1,996	+2.8%	-5.8%

Questions

What was Opko Health's revenue in Q3 FY2026?

Opko Health (OPK) reported revenue of $65 million for Q3 FY2026, the quarter ended 30 September 2026, up 15.9% on the same quarter a year earlier as the company restated it.

How much did Opko Health earn in Q3 FY2026?

Net loss for Q3 FY2026 was $54 million, and the diluted loss per share $0.07.

When did Opko Health report Q3 FY2026 results?

Opko Health filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 4 November 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024	Q1 FY2025	Q2 FY2025	Q3 FY2025 †	Q4 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	401	329	310	180	185	238	265	179	182	174	182	174	184	150	157	152	148	124	164	65.4
Cost of revenue	293	244	194	148	129	138	n/a	n/a	n/a	132	131	134	99.0	107	107	21.4	84.4	78.4	83.6	23.4
Gross profit	109	85.3	116	31.3	56.0	99.3	n/a	n/a	n/a	42.1	51.7	40.1	84.7	42.6	49.4	49.9	64.0	45.8	80.0	42.1
Gross margin	27%	26%	37%	17%	30%	42%	n/a	n/a	n/a	24%	28%	23%	46%	28%	32%	33%	43%	37%	49%	64%
R&D	21.0	18.3	17.3	18.8	19.5	32.6	18.2	19.4	19.4	21.9	24.1	28.8	30.4	30.8	30.3	29.8	32.8	29.2	33.2	32.2
SG&A	138	118	101	79.7	74.0	75.6	79.8	72.2	72.9	70.2	68.8	98.2	67.0	59.1	59.6	53.8	50.5	48.6	52.9	24.8
Operating income	-63.1	-72.4	-10.7	-87.8	-55.3	-30.6	7.0	-64.4	-69.0	-71.5	-61.7	14.2	-33.1	-67.2	-60.0	48.1	-38.3	-51.0	-7.0	-31.4
Operating margin	-16%	-22%	-3%	-49%	-30%	-13%	3%	-36%	-38%	-41%	-34%	8%	-18%	-45%	-38%	32%	-26%	-41%	-4%	-48%
Interest expense	n/a	n/a	3.1	3.0	n/a	3.4	3.3	3.4	3.5	7.7	8.2	17.4	14.2	15.5	70.3	11.3	11.3	10.9	11.4	13.5
Pre-tax income	-65.8	-76.7	-86.3	-126	-102	-17.0	-16.4	-78.4	-72.5	-83.2	-10.6	48.4	35.0	-73.4	-163	-41.0	-46.9	-61.0	-13.4	-42.9
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	49%	60%	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Net income	-73.8	-55.4	-102	-86.1	-85.2	-18.3	-19.6	-84.5	-66.5	-81.8	-10.3	24.9	14.0	-67.6	-148	21.6	-31.3	-54.8	-8.4	-53.5
Net margin	-18%	-17%	-33%	-48%	-46%	-8%	-7%	-47%	-37%	-47%	-6%	14%	8%	-45%	-95%	14%	-21%	-44%	-5%	-82%
Diluted EPS	-$0.11	-$0.08	-$0.14	-$0.11	-$0.11	-$0.02	-$0.03 basic	-$0.11	-$0.09 basic	-$0.12	-$0.01	$0.03	$0.01	-$0.10	-$0.19	$0.03	-$0.04	-$0.07	-$0.01	-$0.07
Operating cash flow	-5.6	-19.9	-11.5	-32.2	-31.6	-22.6	-0.4	33.1	-38.3	-35.6	-26.4	-77.1	-44.4	-34.6	-83.4	-34.6	-25.9	-19.3	-43.5	-36.3
Capital expenditure	6.7	5.3	5.4	7.6	6.3	3.0	6.0	4.2	3.0	4.4	7.2	7.9	5.4	3.2	3.3	3.1	2.7	1.8	3.0	2.8
Free cash flow	-12.4	-25.1	-16.9	-39.8	-38.0	-25.7	-6.4	28.9	-41.3	-40.0	-33.7	-85.0	-49.8	-37.7	-86.7	-37.8	-28.6	-21.1	-46.5	-39.1
Buybacks	n/a	n/a	n/a	n/a	n/a	0.0	0.0	0.0	0.0	50.0	0.0	23.8	16.5	0.0	18.3	15.3	13.5	4.8	13.0	10.6
Shares outstanding	681m	682m	772m	773m	773m	773m	773m	773m	697m	697m	697m	682m	672m	793m	794m	768m	759m	755m	746m	743m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 4 November 2026: the filing.